In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), with a price target of $26.00. The company’s shares closed yesterday at $10.84.
Raycroft covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, KalVista Pharmaceuticals, and BioCryst. According to TipRanks, Raycroft has an average return of 6.6% and a 38.46% success rate on recommended stocks.
Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $20.67, representing a 90.68% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $16.23 and a one-year low of $4.12. Currently, KalVista Pharmaceuticals has an average volume of 200.4K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KALV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
Read More on KALV:
